封面
市場調查報告書
商品編碼
1226725

動物用皮膚治療藥的全球市場:現狀分析、預測(2022年~2028年)

Veterinary Dermatology Drugs Market: Current Analysis and Forecast (2022-2028)

出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 159 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球動物用皮膚治療藥的市場規模,由於技術進步和動物用製藥公司投資增加,以約9%穩定成長。還有主要企業急速投入新產品,對市場成長帶來好影響。再加上養寵物的人數擴大,對寵物的更佳治療選擇的需求劇增,市場預期以驚異性的速度成長。

本報告提供全球動物用皮膚治療藥市場相關調查分析,各市場區隔、各地區的市場洞察,市場動態,市場趨勢,競爭情形,企業簡介等系統性資訊。

目錄

第1章 市場簡介

第2章 調查手法、前提條件

第3章 市場概要

第4章 摘要整理

第5章 COVID-19對動物用皮膚治療藥市場的影響

第6章 動物用皮膚治療藥市場收益(2020年~2028年)

第7章 市場洞察:各動物類型

  • 寵物
  • 家畜動物

第8章 市場洞察:各給藥途徑

  • 局部
  • 注射
  • 口服

第9章 市場洞察:各症狀

  • 寄生蟲感染疾病
  • 過敏感染疾病
  • 其他

第10章 市場洞察:各流通管道

  • 零售
  • 電子商務
  • 院內藥局

第11章 市場洞察:各地區

  • 北美
    • 美國
    • 加拿大
    • 其他北美
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他地區

第12章 動物用皮膚治療藥:市場動態

  • 推動市場要素
  • 市場課題
  • 影響分析

第13章 動物用皮膚治療藥:市場機會

第14章 動物用皮膚治療藥:市場趨勢

第15章 需求方面、供給側面的分析

  • 需求面分析
  • 供給側面分析

第16章 價值鏈分析

第17章 競爭模式

  • 競爭情形
    • 波特的五力分析

第18章 企業概要

  • Elanco
  • Vetoquinol
  • CEVA
  • Zoetis
  • Vivaldis
  • Bimeda, Inc.
  • Boehringer Ingelheim
  • Bayer
  • Merck KGaA
  • Mars, Incorporated

第19章 免責聲明

簡介目錄
Product Code: UMME211612

Veterinary dermatology drugs refer to the medications which are indicated for the management of harmful, deadly skin infections, such as parasitic skin diseases, dander-related skin disorders, alopecia, intrinsic skin infections, autoimmune skin diseases, mild and harmful skin cancer, and other internal causes for skin abnormalities. The veterinary dermatology drugs market is anticipated to grow at a tremendous rate owing to the increase in the number of pet owners and the surge in demand for better treatment options for companion animals. For instance, as of 2021, 3.2 million families in the United Kingdom had added a pet since the pandemic's commencement, according to the Pet Food Manufacturers Association. With 12 million cats, 12 million dogs, 3.2 million small mammals like guinea pigs and hamsters, 3 million birds, and 1.5 million reptiles, there are currently 34 million pets in the United Kingdom.

The Veterinary Dermatology Drugs Market is expected to grow at a steady rate of around 9% owing to rise in technological advancements and an increase in investment by veterinary pharmaceutical firms. The key players are rapidly launching novel products, which are also having a positive impact on market growth. For instance, in 2022, Vetoquinol launched PHOVIA in Canada, which is an innovative system that aims to lessen the challenges of the current standard of care through the use of Fluorescent Light Energy (FLE). Although this technology is already used in human medicine, Vetoquinol is the pioneer of its use in the veterinary world.

Based on animal type, the market is segmented into companion animal and livestock animal. The companion animal held the dominant share of the market in 2020 due to a surge in the number of pet owners. According to the annual report of the European Pet Food Industry Association (FEDIAF), published in July 2022, cats and dogs are the most common companion animals in Europe, with 26% of all pet-owning households owning a cat, or 110 million household cats, and 25% owned dogs or 90 million dogs. Thus, this trend is anticipated to drive segmental growth during the forthcoming years.

On the basis of route of administration, the market is categorized into topical, injectable, and oral. The injectable category is expected to grow with high CAGR during the forecast period as it allows accessible administration in lesser number of doses in comparison to oral drugs. For instance, Convenia by Zoetis treats the animal in only one dose as compared to 28 doses of pills.

On the basis of indication, the market is segmented into parasitic infections, allergic infections, and others. The parasitic infections held a significant share of the market in 2020 due to the surge in the incidences of parasitic infections among animals. According to WebMD, a study conducted by Colorado State University in May 2021, found Lyme disease-carrying ticks, abundantly near beaches of Northern California, the U.S.

On the basis of distribution channel, the market is segmented into retail, e-commerce, and hospital pharmacies. The e-commerce segment is expected to grow with a high CAGR during the forecast period which is attributable to the rising penetration of veterinary products specific e-commerce websites and veterinary telehealth platforms. For example, in 2020, Vetster launched an innovative pet wellness platform through which pet owners can schedule appointments using voice, video, and chat that connects them to a market of qualified veterinary practitioners. Thus, these advancements is anticipated to drive segmental growth during the forecast period.

For a better understanding of the market adoption of the veterinary dermatology drugs, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. Several factors, such as rising medical & diagnostic capabilities for companion animals and increasing ownership of companion animals is expected to support the growth and demand for veterinary dermatology drugs in the region. Apart from this, Asia Pacific is home to manufacturing facilities of keys players in the market, such as Elanco, which further boosts growth.

Some of the major players operating in the market include: Elanco; Vetoquinol; CEVA; Zoetis; Vivaldis; Bimeda, Inc.; Boehringer Ingelheim; Bayer; Merck KGaA; and Mars, Incorporated.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Veterinary Dermatology Drugs Market
  • 2.2. Research Methodology of the Veterinary Dermatology Drugs Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE VETERINARY DERMATOLOGY DRUGS MARKET

6 VETERINARY DERMATOLOGY DRUGS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY ANIMAL TYPE

  • 7.1. Companion Animal
  • 7.2. Livestock Animal

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

  • 8.1. Topical
  • 8.2. Injectable
  • 8.3. Oral

9 MARKET INSIGHTS BY INDICATION

  • 9.1. Parasitic Infections
  • 9.2. Allergic Infections
  • 9.3. Others

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 10.1. Retail
  • 10.2. E-Commerce
  • 10.3. Hospital Pharmacies

11 MARKET INSIGHTS BY REGION

  • 11.1. North America
    • 11.1.1. U.S.
    • 11.1.2. Canada
    • 11.1.3. Rest of North America
  • 11.2. Europe
    • 11.2.1. Germany
    • 11.2.2. U.K.
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. Asia-Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Rest of Asia-Pacific
  • 11.4. Rest of World

12 VETERINARY DERMATOLOGY DRUGS MARKET DYNAMICS

  • 12.1. Market Drivers
  • 12.2. Market Challenges
  • 12.3. Impact Analysis

13 VETERINARY DERMATOLOGY DRUGS MARKET OPPORTUNITIES

14 VETERINARY DERMATOLOGY DRUGS MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 15.1. Demand Side Analysis
  • 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

  • 17.1. Competitive Landscape
    • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

  • 18.1. Elanco
  • 18.2. Vetoquinol
  • 18.3. CEVA
  • 18.4. Zoetis
  • 18.5. Vivaldis
  • 18.6. Bimeda, Inc.
  • 18.7. Boehringer Ingelheim
  • 18.8. Bayer
  • 18.9. Merck KGaA
  • 18.10. Mars, Incorporated

19 DISCLAIMER